File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

TitleImproving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma
Authors
Beishuizen, AMellgren, KAndres, MAuperin, ABacon, CMBomken, SBurke, GAABurkhardt, BBrugieres, LChiang, AKSDamm-Welk, Cd'Amore, EHoribe, KKabickova, EKhanam, TKontny, UKlapper, WLamant, LLe Deley, MCLoeffen, JMacintyre, EMann, GMeyer-Wentrup, FMichgehl, UMinard-Colin, VMussolin, LOschlies, IPatte, CPillon, MReiter, ARigaud, CRoncery, LSalaverria, ISimonitsch-Klupp, IUyttebroeck, AVerdu-Amoros, JWilliams, DWoessmann, WWotherspoon, AWrobel, GZimmermann, MAttarbaschi, ATurner, SD
Issue Date1-Mar-2023
PublisherElsevier
Citation
The Lancet Haematology, 2023, v. 10, n. 3, p. e213-e224 How to Cite?
DOI: http://dx.doi.org/10.1016/s2352-3026(22)00374-X
Abstract

The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) was established 25 years ago with the goal to facilitate clinical trials and research collaborations in the field both within Europe and worldwide. Since its inception, much progress has been made whereby major improvements in outcomes have been achieved. In this Review, we describe the different diagnostic entities of non-Hodgkin lymphoma in children and young adults describing key features of each entity and outlining clinical achievements made in the context of the EICNHL framework. Furthermore, we provide an overview of advances in biopathology with an emphasis on the role of biological studies and how they have shaped available treatments. Finally, for each entity, we describe future goals, upcoming clinical trials, and highlight areas of research that require our focus going forward.


Persistent Identifierhttp://hdl.handle.net/10722/328971
ISSN
2352-3026
2021 Impact Factor: 30.153
2020 SCImago Journal Rankings: 5.343

 

DC FieldValueLanguage
dc.contributor.authorBeishuizen, A-
dc.contributor.authorMellgren, K-
dc.contributor.authorAndres, M-
dc.contributor.authorAuperin, A-
dc.contributor.authorBacon, CM-
dc.contributor.authorBomken, S-
dc.contributor.authorBurke, GAA-
dc.contributor.authorBurkhardt, B-
dc.contributor.authorBrugieres, L-
dc.contributor.authorChiang, AKS-
dc.contributor.authorDamm-Welk, C-
dc.contributor.authord'Amore, E-
dc.contributor.authorHoribe, K-
dc.contributor.authorKabickova, E-
dc.contributor.authorKhanam, T-
dc.contributor.authorKontny, U-
dc.contributor.authorKlapper, W-
dc.contributor.authorLamant, L-
dc.contributor.authorLe Deley, MC-
dc.contributor.authorLoeffen, J-
dc.contributor.authorMacintyre, E-
dc.contributor.authorMann, G-
dc.contributor.authorMeyer-Wentrup, F-
dc.contributor.authorMichgehl, U-
dc.contributor.authorMinard-Colin, V-
dc.contributor.authorMussolin, L-
dc.contributor.authorOschlies, I-
dc.contributor.authorPatte, C-
dc.contributor.authorPillon, M-
dc.contributor.authorReiter, A-
dc.contributor.authorRigaud, C-
dc.contributor.authorRoncery, L-
dc.contributor.authorSalaverria, I-
dc.contributor.authorSimonitsch-Klupp, I-
dc.contributor.authorUyttebroeck, A-
dc.contributor.authorVerdu-Amoros, J-
dc.contributor.authorWilliams, D-
dc.contributor.authorWoessmann, W-
dc.contributor.authorWotherspoon, A-
dc.contributor.authorWrobel, G-
dc.contributor.authorZimmermann, M-
dc.contributor.authorAttarbaschi, A-
dc.contributor.authorTurner, SD-
dc.date.accessioned2023-08-05T07:54:19Z-
dc.date.available2023-08-05T07:54:19Z-
dc.date.issued2023-03-01-
dc.identifier.citationThe Lancet Haematology, 2023, v. 10, n. 3, p. e213-e224-
dc.identifier.issn2352-3026-
dc.identifier.urihttp://hdl.handle.net/10722/328971-
dc.description.abstract<p>The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) was established 25 years ago with the goal to facilitate clinical trials and research collaborations in the field both within Europe and worldwide. Since its inception, much progress has been made whereby major improvements in outcomes have been achieved. In this Review, we describe the different diagnostic entities of non-Hodgkin lymphoma in children and young adults describing key features of each entity and outlining clinical achievements made in the context of the EICNHL framework. Furthermore, we provide an overview of advances in biopathology with an emphasis on the role of biological studies and how they have shaped available treatments. Finally, for each entity, we describe future goals, upcoming clinical trials, and highlight areas of research that require our focus going forward.</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofThe Lancet Haematology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleImproving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/s2352-3026(22)00374-X-
dc.identifier.scopuseid_2-s2.0-85149217282-
dc.identifier.volume10-
dc.identifier.issue3-
dc.identifier.spagee213-
dc.identifier.epagee224-
dc.identifier.eissn2352-3026-
dc.identifier.issnl2352-3026-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats